Humacyte, Inc. (HUMA)
(Delayed Data from NSDQ)
$8.25 USD
-0.37 (-4.29%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $8.33 +0.08 (0.97%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for Humacyte, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 80 | 152 | 226 | 1 | -99,999 |
Receivables | 0 | 0 | 0 | 0 | NA |
Notes Receivable | 0 | 0 | 0 | 0 | NA |
Inventories | 0 | 0 | 0 | 0 | NA |
Other Current Assets | 3 | 2 | 4 | 0 | NA |
Total Current Assets | 83 | 154 | 229 | 1 | NA |
Net Property & Equipment | 27 | 30 | 35 | 0 | NA |
Investments & Advances | 0 | 0 | 0 | 100 | NA |
Other Non-Current Assets | 0 | 0 | 0 | 0 | NA |
Deferred Charges | 0 | 0 | 0 | 0 | NA |
Intangibles | 0 | 0 | 0 | 0 | NA |
Deposits & Other Assets | 18 | 19 | 21 | 0 | NA |
Total Assets | 128 | 204 | 287 | 101 | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 9 | 0 | 0 | NA |
Accounts Payable | 6 | 2 | 2 | 0 | NA |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Current Portion Capital Leases | 3 | 2 | 2 | 0 | NA |
Accrued Expenses | 9 | 7 | 7 | 0 | NA |
Income Taxes Payable | 0 | 0 | 0 | 0 | NA |
Other Current Liabilities | 0 | 0 | 0 | 0 | NA |
Total Current Liabilities | 18 | 20 | 11 | 0 | NA |
Mortgages | 0 | 0 | 0 | 0 | NA |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | NA |
Convertible Debt | 0 | 0 | 0 | 0 | NA |
Long-Term Debt | 0 | 20 | 27 | 0 | NA |
Non-Current Capital Leases | 16 | 19 | 21 | 0 | NA |
Other Non-Current Liabilities | 80 | 28 | 104 | 96 | NA |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | NA |
Total Liabilities | 115 | 87 | 164 | 96 | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | NA |
Common Stock (Par) | 0 | 0 | 0 | 0 | NA |
Capital Surplus | 551 | 543 | 537 | 5 | NA |
Retained Earnings | -537 | -427 | -415 | 0 | NA |
Other Equity | 0 | 0 | 0 | 0 | NA |
Treasury Stock | 0 | 0 | 0 | 0 | NA |
Total Shareholder's Equity | 14 | 117 | 122 | 5 | NA |
Total Liabilities & Shareholder's Equity | 128 | 204 | 287 | 101 | NA |
Total Common Equity | 14 | 117 | 122 | 5 | 0 |
Shares Outstanding | 103.60 | 103.20 | 103.00 | 12.80 | NA |
Book Value Per Share | 0.13 | 1.13 | 1.19 | 0.39 | 0.00 |
Fiscal Year End for Humacyte, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 116 | 80 | 100 | 115 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 2 | 3 | 3 | 6 |
Total Current Assets | NA | 118 | 83 | 103 | 121 |
Net Property & Equipment | NA | 26 | 27 | 28 | 29 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 18 | 18 | 19 | 18 |
Total Assets | NA | 161 | 128 | 149 | 168 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 3 | 6 | 3 | 2 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 3 | 3 | 2 | 2 |
Accrued Expenses | NA | 8 | 9 | 10 | 7 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 14 | 18 | 15 | 11 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 16 | 16 | 17 | 18 |
Other Non-Current Liabilities | NA | 80 | 80 | 78 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 135 | 115 | 112 | 107 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 595 | 551 | 549 | 547 |
Retained Earnings | NA | -569 | -537 | -512 | -486 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 26 | 14 | 37 | 61 |
Total Liabilities & Shareholder's Equity | NA | 161 | 128 | 149 | 168 |
Total Common Equity | 0 | 26 | 14 | 37 | 61 |
Shares Outstanding | 119.00 | 119.00 | 103.60 | 103.40 | 103.40 |
Book Value Per Share | 0.00 | 0.22 | 0.13 | 0.36 | 0.59 |